Plain-English translation of NCT07416526 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called NXT007 designed to help prevent bleeding episodes in people with moderate to severe hemophilia A. You would receive either NXT007 or the standard Factor VIII preventive treatment that you may already be taking. The study will compare how well each treatment works, how safe it is, and how long it stays in your body.
People with hemophilia A need ongoing preventive treatment to avoid dangerous bleeding, but current options require frequent injections and may not work perfectly for everyone. This trial is testing whether this medication could offer a better or more convenient way to prevent bleeds.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either NXT007 or your current Factor VIII preventive treatment during the main study period. You would visit the clinic regularly so doctors can check how well the treatment is working, monitor your bleeding episodes, and test your blood. After the main study ends, you would have the option to continue or switch to NXT007 in an extended phase, allowing researchers to gather longer-term safety and effectiveness information.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
Japan